Global Hemangioma Treatment Market

Global Hemangioma Treatment Market is expected to reach US$ 405.36 Mn by 2032 from US$ 318.61 Mn in 2025, at a CAGR of 3.5 % during forecast period.

Global Hemangioma Treatment Market Overview:

A Hemangioma is a bright red a birthmark that appears at birth or during the first two weeks after birth. A hemangioma can appear anywhere on the body, but they're most common on the face, scalp, chest, and back. Hemangioma is a benign or non-cancerous blood vessel tumour that appears as a rubbery bump on the skin.

Global Hemangioma Treatment Market Dynamics:

Rising prevalence of Hemangioma is expected to majorly drive the market growth.

Globally, the prevalence of hemangioma in infants is around 5% to 10% suffering from this disease. Girls, premature babies, twins, and triplets are the most common victims of this disease, and it is most common in Caucasians. The research studies state that spinal hemangioma affects about 10% of the world's population, necessitating further care. Spinal hemangioma is most common in people between the ages of 30 and 50, and it sometimes goes unnoticed. During the forecast period, the market is expected to be fuelled by proper diagnosis and an increase in minimally invasive procedures for removing tumors found in the body's internal organs. The increase in the number of cases being reported each day across the world, as well as the introduction of improved care options, are factors that could contribute to a high growth rate in the coming years. The industry is also expected to make substantial gains as more drugs are used and medication therapies are used. Moreover, ongoing technological advancements, raising awareness about the disease, and rising investment in research and development of new treatment options are expected to aid the market growth.

However, certain factors are expected to hamper the market growth. The side effects associated with surgical laser procedures, high cost for the treatment of hemangioma and strict approval policies are anticipated to hinder the market growth.

The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Hemangioma Treatment Market Segment Analysis:

The Global Hemangioma Treatment Market is segmented on the basis of Type, Diagnosis and Treatment.

Based on type, the infantile hemangioma segment is expected to dominate the global market during the forecast period. Hemangiomas in children are benign vascular neoplasms that involve early proliferation and spontaneous involution. Hemangiomas are the most common tumors in children, and they are typically medically unimportant. The prevalence of infantile hemangioma is 4-5%, and the rise in the prevalence of hemangioma, especially in non-hispanic white female babies, may drive the infantile hemangioma market.

Based on the treatment, the beta-blocker drugs segment is expected to hold a larger market share as it is the commonly used medication. The beta-blockers segment consists of drugs such as propranolol, timolol, atenolol, nadolol. A gel containing the drug timolol may be applied to the infected skin in case of superficial hemangiomas. If treated with an oral solution of propranolol, a serious infantile hemangioma can disappear.

To know about the Research Methodology :- Request Free Sample Report

Recent Development: Global Hemangioma Treatment Market

Global Hemangioma Treatment Market Regional Insights:

North America holds the dominant market share.

North America region is expected to continue the dominance during the forecast period. Due to a higher number of minimally invasive procedures, an increase in infantile hemangioma, and an increase in adult hemangioma cases, North America is expected to dominate the global hemangioma treatment market during the forecast period. Another factor driving the market in North America is the presence of key players in the area who provide a variety of oral and topical medications for the treatment of hemangioma. Followed by North America, Europe holds the second largest market share. An increase in research and development projects is expected to aid market growth.

The report also helps in understanding Global Hemangioma Treatment Market dynamics, structure by analyzing the market segments and project the Global Hemangioma Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Hemangioma Treatment Market make the report investor’s guide.

Global Hemangioma Treatment Market Scope:
Inquire before buying

Global Hemangioma Treatment Market, By Region:

• North America
• Europe
• South America
• MEA
• APAC

Global Hemangioma Treatment Market, Key players

• Pierre Fabre Laboratories
• Pfizer Inc.
• Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Reddy’s Laboratories Ltd.
• Eton Pharmaceuticals Inc.
• Allergan plc
• Akorn Operating Company LLC
• Novartis AG
• AstraZeneca plc
• GlaxoSmithKline plc
• Candela Corporation
• Cutera Inc.
• Lumenis Ltd.
• Alma Lasers
• Syneron Medical Ltd.
• BIOLASE Inc.
• IRIDEX Corporation
• Medtronic plc
• Boston Scientific Corporation
• Penumbra Inc.
• Hanmi Pharmaceutical Co. Ltd.
• Chugai Pharmaceutical Co. Ltd.
• LINLINE Medical Systems
• Valeant Pharmaceuticals
• Mylan N.V.